Authors
Hubert de Boysson, Nanti Esther Adoukonou, Anael Dumont, Thibault Orvain, Jonathan Boutemy, Claire Delacotte, Sophie Gallou, Antoine Hankard, Gwénola Maigné, Nicolas Martin Silva, Rémi Philip, Marine Trenec, Amélia Rocamora, Samuel Deshayes, Achille Aouba
Published in
Joint bone spine. Pages 106160. Nov 03, 2026. Epub Nov 03, 2026.
Abstract
Giant cell arteritis (GCA) is the most common systemic vasculitis in adults over 50. Tocilizumab (TCZ), the first biologic approved in GCA, enables glucocorticoid-sparing remission, but reliable predictors of treatment outcome at initiation are lacking. We aimed to identify baseline and follow-up predictors of TCZ failure in GCA.
In this retrospective single-centre cohort study, consecutive GCA patients receiving their first TCZ course at Caen University Hospital (2014-2024) were included, excluding early withdrawal (<3 months). Two multivariable logistic regression models were built using backward stepwise elimination: a baseline model and a combined baseline-and-follow-up model incorporating FDG-PET/CT metabolic response.
Of 91 patients, TCZ was successful in 43 (47%) and failed in 48 (53%). Baseline multivariable analysis identified three predictors of failure: CRP > 63.5 mg/L (OR 3.40; 95% CI 1.26-9.77; P<0.05), large-vessel vasculitis (LVV; OR 3.22; 95% CI 1.18-9.44; P<0.05) and previous relapse before TCZ (OR 3.75; 95% CI 1.16-9.41; P<0.05). A predictive score yielded an AUC of 0.774 (95% CI 0.674-0.873). In the combined follow-up model, PET/CT extinction status was significantly associated with treatment outcome overall (P<0.001). A longer duration of TCZ exposure was associated with a lower risk of failure (OR 0.911 per additional month, 95% CI 0.822-0.997; P<0.05).
Baseline CRP, LVV and prior relapses can be combined into a simple predictive score to stratify the probability of TCZ response in GCA. Complete metabolic extinction on FDG-PET/CT during treatment further identifies patients at risk of failure.
PMID:
42977214
Bibliographic data and abstract were imported from PubMed on 04 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 15
- Comments 0